Navigation Links
Omeros is Not Aware of Any Justification for Share Price Movement
Date:11/13/2012

SEATTLE, Nov. 13, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) has noted the fall in its share price over the last week of trading.  Omeros is not aware of any reason that justifies this decrease. As disclosed in Omeros' recent press releases and its Quarterly Report on Form 10-Q filed on November 9, 2012 with the US Securities and Exchange Commission, Omeros' business, including its clinical programs and its preclinical pipeline, remains on track and the Company is pleased with its progress.

About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has four ongoing clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.


'/>"/>
SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Omeros to Present at Deutsche Bank Securities Health Care Conference
2. Omeros Adds Four More Unlocked Orphan GPCRs to its Portfolio
3. Omeros to Present at Jefferies 2012 Global Healthcare Conference
4. Omeros Announces Proposed Public Offering of Common Stock
5. Omeros Prices $30 Million Public Offering of Common Stock
6. Omeros Announces Closing of $34.5 Million Public Offering of Common Stock
7. Omeros Successfully Completes Preclinical Studies of OMS824 for Schizophrenia and Phase 1 Clinical Trial Preparations Underway
8. Omeros Announces Discovery in MASP-2 Program
9. Omeros Corporation Reports Second Quarter 2012 Financial Results
10. Omeros Announces Completion of Enrollment in OMS103HP Phase 3 Clinical Trial
11. Omeros to Present at Two Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2017)... 1, 2017 Nutriceutical Holdings (NH), parent company ... (VRS), and KD Pharma Group have decided to join ... KD Pharma Group. KD Pharma Group will become the ... acquire the entire company. "We believe we ... committed to growing the NH companies by providing us ...
(Date:5/26/2017)... -- Endo International plc (NASDAQ: ENDP ) announced today ... the Company in a fireside chat at Goldman Sachs, 38 ... 2017 at 10:40 a.m. PT / 1:40 p.m. ET. The ... Rancho Palos Verdes, CA. A live ... on the Company,s website at http://www.endo.com/investors/overview . Participants should ...
(Date:5/22/2017)... MAITLAND, Fla. , May 22, 2017 /PRNewswire/ ... industry as a whole continue to make the ... evidence becomes increasingly important for ensuring positive patient ... Key industry stakeholders are shifting focus away from ... results and effects of long-term specialty drug therapy ...
Breaking Medicine Technology:
(Date:6/20/2017)... Murfreesboro, Tennessee (PRWEB) , ... June 20, 2017 ... ... chronic care services, announced today that Claritas Capital, a Nashville-based private equity firm, ... to accelerate our expansion plans for some time, and Claritas Capital offers the ...
(Date:6/20/2017)... ... June 20, 2017 , ... Hayes, ... published a new eBook titled “ 5 Questions to Ask Before Entering the ... on the Genetic Test Evaluation (GTE) team, the book explores the various types ...
(Date:6/20/2017)... ... June 20, 2017 , ... AMC Health , ... and success in the clinical trials market. Similar to its approach in demonstrating positive ... the clinical trials marketplace by proving the value of eVisits to support virtual studies. ...
(Date:6/20/2017)... ... June 20, 2017 , ... With certifications and experience that ... Denville, NJ, Drs. Adam and Hal Kimowitz are currently accepting new patients at their ... orthodontics can cause for some patients, which is why they offer the latest in ...
(Date:6/20/2017)... ... 20, 2017 , ... Uniform Advantage (UA), a multi-channel retailer of ... to create tailored looks and athleisure-inspired outfits. UA Flex fabric is breathable, wrinkle resistant ... , With trendy looks hitting the medical community, UA Flex is for the medical ...
Breaking Medicine News(10 mins):